Invega Sustenna (paliperidone palmitate) is a prescription drug that’s used to treat schizophrenia and schizoaffective disorder. Invega Sustenna is given as an injection into your muscle by a ...

Subjects from any oral antipsychotic medication could be switched to an effective dose of paliperidone ER without the need for titration. Subjects could be cross-tapered in different ways from ...

If you are worried about using this medicine, speak to your doctor or pharmacist. INVEGA HAFYERA contains the active ingredient paliperidone palmitate. INVEGA HAFYERA is used to treat ...

Johnson & Johnson said on Monday it would buy neurological drug maker Intra-Cellular Therapies for $14.6 billion, its biggest ...

Vadodara: Alembic Pharmaceuticals Limited has announced that it has received Final Approval from the US Food & Drug ...

The period is expected to feature launches of new branded drugs, along with tough years for the long-acting injectables (LAI) Abilify Maintena, Aristada and Invega Sustenna, all of which are set ...

JNJ is set to acquire ITCI for $132 per share in cash. The transaction is likely to close before this year's end.

A key rival could be Johnson & Johnson's recently-approved Invega Hafyera (paliperidone ... Since then, newer new drugs Austedo (deutetrabenazine) for Huntington's disease and migraine therapy ...

Cellular’s neuropsychiatric assets is Caplyta, a pill approved for schizophrenia and bipolar depression and proposed for ...

In 2024, the Rx IP Update team at Smart & Biggar reported on a number of developments in Canadian life sciences IP and ...

unsealed ruling shows Schizophrenia drug had nearly $3 billion in US sales in 2023 Johnson & Johnson’s Janssen Pharmaceuticals Inc. unit convinced a federal judge that unexpected results and industry ...